CalciMedica, Inc.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, an inhibitor of neovascular growth and permeability, which are causes of retinal disease. It is developing GB-102 as a once-every-six months intravitreal injection for the treatment of wet age-related macular degeneration or wet (AMD), and diabetic macular edema (DME). It is also using its technologies to develop GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy (DR), as well as GB-401, an intravitreally injectable depot formulation of a beta-adrenergic blocking agent prodrug with a dosing regimen of once every six months or longer for the treatment of primary open-angle glaucoma (POAG).